PROBLEM TO BE SOLVED: To provide a sustained-release preparation for injection that lasts effective blood concentration, which relates to an insoluble drug useful for treatment of schizophrenia, bipolar disorder, depression, etc.SOLUTION: According to the present invention, s suspension preparation for injection for intramuscular administration or subcutaneous administration, the preparation comprising: (1) N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl] - (1R,2S,3R,4S) -2,3-bicyclo [2,2,1] heptanedicarboximide or a pharmaceutically acceptable acid addition salt thereof (here, the active ingredient is crystalline and the crystal has an average particle size of about 4 μm to about 26 μm) (2) a surfactant containing at least one selected from polysorbate 80, etc. (3) one or more buffer agents selected from sodium hydrogen phosphate, etc. and (4) one or more tonicity agents selected from sodium chloride, etc. and (5) water for injection.SELECTED DRAWING: NoneCOPYRIGHT: (C)2018,JPO&INPIT【課題】統合失調症、双極性障害、うつ病等の治療に有用な難溶性薬物に関し、有効な血中濃度を持続する注射用徐放性製剤の提供。【解決手段】(1)N-[4-〔4-(1,2-ベンズイソチアゾール-3-イル)-1-ピペラジニル〕-(2R,3R)-2,3-テトラメチレン-ブチル]-(1’R,2’S,3’R,4’S)-2,3-ビシクロ〔2,2,1〕ヘプタンジカルボキシイミド又はその薬学上許容される酸付加塩(ここで活性成分は結晶であり、結晶の平均粒子径は約4μm~約26μmである);(2)ポリソルベート80等から選択される少なくとも1種を含む界面活性剤;(3)リン酸水素二ナトリウム等から選択される1種以上の緩衝剤;(4)塩化ナトリウム等から選択される1種以上の等張化剤;並びに(5)注射用水を含有する筋肉内投与用又は皮下投与用の注射用懸濁製剤。【選択図】なし
